Signablok, Inc.
Worcester, MA
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 61 Frank St #36, Worcester, MA 01604, USA
- Website
- signablok.com
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| DHA medical R & D, sbir phase I purchase order for proposal no. H201-002-0001 titled,"first-in-class trem-1… | Medical Command (Army) | $220,006 | |
| Contract award | ACC Aberdeen Proving Ground | $149,950 |
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| The University Of Texas Health Science Center At Tyler | R61HL175690 | $200,604 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Oasis Pharmaceuticals, LLC | Lexington, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Eldec Pharmaceuticals, Inc. | Durham, NC | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Cytoagents Inc. | Pittsburgh, PA | 325412 Pharmaceutical Preparation Manufacturing |
| Human Cell Co | Naperville, IL | — |
| Aqualung Therapeutics, Corp | Juno Beach, FL | — |
About the company
Signablok, Inc. is a corporate entity registered in SAM.gov since April 22, 2010, with its primary address located in Worcester, Massachusetts. The company appears to be a biotechnology research organization focused on developing innovative medical therapies, specifically targeting inflammation and molecular pathways related to various medical conditions. While limited publicly available information exists about the company's full operational scope, its federal grant award history demonstrates a clear specialization in developing novel therapeutic peptide-based interventions that inhibit the TREM-1 receptor to mitigate inflammatory responses across multiple medical domains.
The company has been awarded multiple federal grants from prestigious agencies like the National Institutes of Health, National Heart Lung and Blood Institute, and National Eye Institute, totaling approximately $613,811 in project grant funding between 2023 and 2026. These grants focus on developing first-in-class TREM-1 inhibitor therapies for critical medical conditions, including acute radiation syndrome, empyema, neovascular retinal diseases, and acute respiratory distress syndrome (ARDS). Signablok's research consistently centers on creating ligand-independent TREM-1 inhibitory peptides, particularly sequences named GF9 and GA31, which can be formulated into macrophage-specific lipopeptide complexes to improve therapeutic targeting and efficacy. The company's research aims to address significant medical challenges with mortality rates ranging from 25-45% in conditions like ARDS, retinopathy, and radiation exposure, presenting innovative approaches to suppressing inflammatory responses and potentially improving patient outcomes across multiple critical medical domains.
Quick answers
Is Signablok, Inc. registered in SAM.gov?
Yes. Signablok, Inc.'s SAM.gov registration is active through October 9, 2027.
What is Signablok, Inc.'s CAGE code?
Signablok, Inc.'s CAGE code is 5Z7P9, and its Unique Entity ID (UEI) is JM5UN38YM1H7.
What is Signablok, Inc.'s most recent federal award?
Signablok, Inc.'s most recent federal grant award is Novel medical countermeasure to mitigate potentially lethal acute radiation syndrome (R21AI193495), from National Institute of Allergy and Infectious Diseases (NIH), on September 19, 2025.
On GovTribe
See Signablok, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors